HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jifeng Feng Selected Research

efatutazone

1/2018Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells.
12/2017PPARĪ³ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARĪ³/PTEN/Akt pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jifeng Feng Research Topics

Disease

79Neoplasms (Cancer)
06/2022 - 12/2006
61Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2022 - 06/2002
26Lung Neoplasms (Lung Cancer)
05/2022 - 04/2008
23Breast Neoplasms (Breast Cancer)
11/2021 - 11/2002
18Disease Progression
05/2022 - 07/2011
15Colorectal Neoplasms (Colorectal Cancer)
03/2022 - 01/2013
13Carcinogenesis
04/2022 - 04/2008
12Stomach Neoplasms (Stomach Cancer)
06/2022 - 02/2002
12Adenocarcinoma of Lung
12/2021 - 02/2015
11Neoplasm Metastasis (Metastasis)
06/2022 - 10/2017
11Exanthema (Rash)
01/2022 - 08/2011
10Neutropenia
11/2021 - 08/2011
9Esophageal Squamous Cell Carcinoma
06/2022 - 01/2019
8Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2021 - 04/2014
7Diarrhea
01/2022 - 01/2015
5Leukopenia
01/2022 - 02/2002
5Hypertension (High Blood Pressure)
12/2021 - 01/2021
5Carcinoma (Carcinomatosis)
01/2021 - 06/2017
5Vomiting
01/2020 - 02/2002
5Lymphatic Metastasis
10/2017 - 02/2002
4Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2022 - 04/2016
4Hepatocellular Carcinoma (Hepatoma)
01/2021 - 01/2009
4Nausea
01/2020 - 02/2002
4Stomatitis
01/2018 - 02/2014
4Acne Vulgaris
01/2018 - 02/2014
3Adenocarcinoma
06/2022 - 01/2020
3Pain (Aches)
01/2022 - 01/2018
3Fatigue
01/2022 - 01/2009
3Hodgkin Disease (Hodgkin's Disease)
01/2022 - 12/2019
3Nasopharyngeal Carcinoma
12/2021 - 01/2020
3Brain Neoplasms (Brain Tumor)
01/2021 - 01/2017
3Hypoxia (Hypoxemia)
01/2021 - 01/2019
3Pancreatic Neoplasms (Pancreatic Cancer)
01/2020 - 12/2014
3Esophageal Neoplasms (Esophageal Cancer)
01/2019 - 01/2016
3Inflammation (Inflammations)
10/2018 - 04/2008
3Thrombocytopenia (Thrombopenia)
01/2017 - 08/2011
2Cognitive Dysfunction
04/2022 - 01/2022
2Squamous Cell Carcinoma of Head and Neck
10/2021 - 08/2015

Drug/Important Bio-Agent (IBA)

22Cisplatin (Platino)FDA LinkGeneric
05/2022 - 02/2002
20Biomarkers (Surrogate Marker)IBA
05/2022 - 01/2014
20Long Noncoding RNAIBA
12/2021 - 12/2014
19PlatinumIBA
06/2022 - 12/2006
16Gefitinib (Iressa)FDA Link
01/2022 - 09/2013
15ErbB Receptors (EGF Receptor)IBA
05/2022 - 01/2013
11MicroRNAs (MicroRNA)IBA
01/2022 - 10/2016
10Tyrosine Kinase InhibitorsIBA
01/2022 - 08/2011
10AfatinibIBA
01/2022 - 02/2014
9Proteins (Proteins, Gene)FDA Link
06/2022 - 01/2013
9Pharmaceutical PreparationsIBA
01/2021 - 01/2009
8Rituximab (Mabthera)FDA Link
09/2021 - 04/2014
7Docetaxel (Taxotere)FDA Link
06/2022 - 01/2019
7Paclitaxel (Taxol)FDA LinkGeneric
06/2022 - 07/2011
7Biological ProductsIBA
01/2022 - 04/2016
7DNA (Deoxyribonucleic Acid)IBA
01/2021 - 12/2006
7icotinibIBA
01/2017 - 09/2013
6Carboplatin (JM8)FDA LinkGeneric
10/2021 - 02/2002
5Immune Checkpoint InhibitorsIBA
06/2022 - 01/2020
5camrelizumabIBA
06/2022 - 12/2019
5Alanine Transaminase (SGPT)IBA
01/2022 - 08/2011
5Trastuzumab (Herceptin)FDA Link
01/2021 - 11/2017
5Liver X ReceptorsIBA
02/2019 - 01/2017
5GemcitabineFDA Link
01/2018 - 07/2011
4anlotinibIBA
06/2022 - 01/2021
4Capecitabine (Xeloda)FDA Link
06/2022 - 10/2019
4Cetuximab (Erbitux)FDA Link
05/2022 - 08/2015
4RNA (Ribonucleic Acid)IBA
12/2021 - 01/2019
4Hormones (Hormone)IBA
11/2021 - 01/2019
4Taxoids (Taxanes)IBA
01/2021 - 10/2016
4Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2021 - 08/2011
4Therapeutic UsesIBA
01/2018 - 11/2015
3Oxaliplatin (Eloxatin)FDA LinkGeneric
06/2022 - 10/2007
3apatinibIBA
06/2022 - 10/2014
3Indicators and Reagents (Reagents)IBA
06/2022 - 01/2019
3B7-H1 AntigenIBA
01/2022 - 01/2019
3Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2022 - 01/2020
3Bevacizumab (Avastin)FDA Link
01/2022 - 07/2015
3NivolumabIBA
12/2021 - 01/2019
3Fulvestrant (Faslodex)FDA Link
11/2021 - 01/2011
3Biosimilar PharmaceuticalsIBA
06/2021 - 01/2020
3Monoclonal AntibodiesIBA
01/2021 - 01/2013
3pyrotinibIBA
01/2021 - 10/2019
3Pemetrexed (MTA)FDA Link
01/2021 - 02/2014
3Glutathione Transferase (Glutathione S-Transferase)IBA
01/2020 - 10/2007
3EnzymesIBA
01/2020 - 02/2010
3Messenger RNA (mRNA)IBA
05/2019 - 10/2018
3GW 3965IBA
02/2019 - 02/2017
3LigandsIBA
02/2019 - 01/2018
3T0901317IBA
01/2019 - 01/2017
2osimertinibIBA
05/2022 - 12/2020
2CytokinesIBA
04/2022 - 10/2018
2aumolertinibIBA
01/2022 - 01/2022
2toripalimabIBA
01/2022 - 01/2021
2UbiquitinIBA
01/2022 - 01/2021
2EverolimusFDA Link
10/2021 - 11/2017
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2021 - 01/2017
2Fluorouracil (Carac)FDA LinkGeneric
10/2021 - 01/2014

Therapy/Procedure

60Drug Therapy (Chemotherapy)
06/2022 - 02/2002
46Therapeutics
06/2022 - 11/2002
6Radiotherapy
06/2022 - 12/2002
6Immunotherapy
04/2022 - 01/2018